AI Article Synopsis
- The study focused on identifying resistance-associated mutations (RAMs) in the integrase of different HIV-1 subtypes among patients unexposed to INSTIs.
- Viral RNA was extracted from 53 patients, revealing a mix of HIV-1 subtypes with a notable prevalence of non-B variants.
- Findings indicated that while nonpolymorphic INSTI-RAMs were absent, specific polymorphic mutations were present in a small percentage of patients, underscoring the need for ongoing monitoring of drug resistance.
Article Abstract
Objectives: Resistance-associated mutations (RAMs) in the integrase of different HIV-1 subtypes were investigated in a cohort of patients never exposed to integrase strand transfer inhibitors (INSTIs).
Methods: The viral RNA was extracted from plasma samples of 53 INSTI-naïve patients, and the integrase genetic region was sequenced and analyzed for subtype assignment and drug resistance.
Results: The median viral load at sampling was 5.28 × 104 RNA copies/mL. Bayesian phylogenetic analysis showed 85% of the HIV-1 isolates were non-B subtypes, with a predominance of subtypes C (22.6%) and CRF01_AE (26.4%). A total of 52 and 110 mutations were found in the integrase region of HIV-1 B and non-B subtypes, respectively. Nonpolymorphic INSTI-RAMs were not detected in this study. However, the accessory mutation E157Q was found in 1 patient with CRF02_AG, and the polymorphic mutations L74M/I that may contribute to a reduced susceptibility to INSTIs in the presence of major mutations were observed in 6 (13.3%) patients with non-B subtypes and 1 (12.5%) patient with the B subtype. Polymorphic mutations at positions known to harbor primary and accessory RAMs were also detected in this study.
Conclusion: Our results highlight the importance of monitoring the emergence of INSTI-RAMS before and after the initiation of INSTI-based therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000484692 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir.
Viruses
December 2024
HIV Pathogenesis Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
Islatravir (ISL) is the first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTtI) with novel modes of action. Data on ISL resistance are currently limited, particularly to HIV-1 non-B subtypes. This study aimed to assess prevalent nucleos(t)ide reverse transcriptase inhibitor (NRTI)-resistant mutations in HIV-1 subtype C for their phenotypic resistance to ISL.
View Article and Find Full Text PDFNext-generation sequencing and drug resistance mutations of HIV-1 subtypes in people living with HIV in Sicily, Italy, 2021-2023.
J Glob Antimicrob Resist
December 2024
Department of Health Promotion, Mother and Child Care, Internal Medicine, and Medical Specialties "G D'Alessandro, " University of Palermo, Palermo, Italy; Microbiology and Virology Unit, AOU Policlinico "P. Giaccone", 90127 Palermo, Italy.
Objectives: HIV-1 infection continues to be a significant public health concern, notwithstanding the expanded utilization of antiretroviral treatment (ART), due to the emergence of drug resistance. The prevalence of transmitted drug resistance remains uncertain, particularly concerning integrase inhibitors. This study aimed to assess the extent of HIV resistance in both ART-naïve and experienced individuals living with HIV (PLHIV) at the University Hospital in Palermo, Italy.
View Article and Find Full Text PDFInitial HIV-1 viral load in French Guiana: Factors associated with viral load set point differences.
IJID Reg
December 2024
COREVIH Guyane, Centre hospitalier de Cayenne, Cayenne, French Guiana.
Objectives: HIV viral load set points may vary between virus subtypes and host characteristics. The HIV epidemic in French Guiana entails a mix of viruses and populations of cosmopolitan origins. In this epidemiological context, we aimed to determine whether, at the scale of our territory, we could identify differences in HIV-1 viral load setpoints in our hospital cohort.
View Article and Find Full Text PDFComparison of the Performance of Commercially Available Quantitative Viral Load Assays Using Clinical Samples from Patients from Regions Where Distinct HIV-1 Subtypes Co-Circulate: Potential Implications for Patient Management.
AIDS Res Hum Retroviruses
January 2025
Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
HIV RNA plasma viral load (VL) is the standard surrogate marker to monitor response to antiretroviral treatment (ART). We compared the linearity, repeatability, and concordance of six commercially available HIV RNA VL platforms using clinical samples from patients from Brazilian sites where different HIV-1 subtypes co-circulate. A total of 150 plasma samples from each city were collected in Curitiba, Southern Brazil (subtype C), São Paulo (subtype B), and Santos (BF recombinants), Southeast Brazil.
View Article and Find Full Text PDFK103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine.
Viruses
September 2024
HIV Pathogenesis Research Unit, University of the Witwatersrand, Johannesburg 2193, South Africa.
Article Synopsis
- Doravirine (DOR) is a new HIV treatment that works against some drug-resistant strains, but its effectiveness against non-B subtypes like HIV-1 subtype C is not fully understood.
- The study used South African data to examine how certain known mutations associated with resistance affect DOR susceptibility, finding that mutations such as V106M and Y188L significantly reduce DOR effectiveness.
- The research emphasizes the importance of genotypic drug resistance testing before starting DOR-based therapy, especially in patients with a history of efavirenz or nevirapine treatment failures.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!